PMID- 18438907
OWN - NLM
STAT- MEDLINE
DCOM- 20080617
LR  - 20080527
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 59
IP  - 5
DP  - 2008 May 15
TI  - Safety and usefulness of minor salivary gland biopsy: retrospective analysis of 
      502 procedures performed at a single center.
PG  - 714-20
LID - 10.1002/art.23579 [doi]
AB  - OBJECTIVE: To analyze the safety of our biopsy technique and the effectiveness of 
      minor salivary gland biopsy (MSGB) for the diagnosis of Sjogren's syndrome (SS) 
      and amyloidosis. METHODS: We conducted a retrospective analysis of 452 patients 
      with suspected SS and 50 with suspected amyloidosis and negative periumbilical 
      fat aspiration analysis who underwent MSGB at a single center. Diagnostic 
      evaluation for SS included Schirmer's test, unstimulated whole salivary flow, 
      detection of antinuclear antibodies and anti-SSA/SSB, erythrocyte sedimentation 
      rate, C-reactive protein, IgM rheumatoid factor, and serology for hepatitis C 
      virus. For all biopsy samples, a cumulative focus score on multilevel sections 
      was calculated. SS was diagnosed according to American-European Consensus Group 
      (AECG) criteria. Histologic evaluation for amyloidosis was performed using Congo 
      red staining and polarized-light microscopy. Adverse events were recorded on a 
      questionnaire immediately after the procedure and 7 days, 14 days, and 6 months 
      thereafter. RESULTS: Sixty-four patients (12.7%) reported transient adverse 
      events: 40 paresthesias lasting <7 days, 17 paresthesias lasting <14 days, 27 
      cases of local swelling, and 8 external hematoma. One patient has had local 
      paresthesia for 2 years. A total of 498 (99.2%) samples provided adequate 
      material for histologic analysis. Of 452 patients evaluated for SS, 378 were 
      finally evaluated. Ninety-three patients (24.5%) had a cumulative focus score > 
      or =1, and 87 (94.5%) of 93 satisfied the AECG criteria. Classification of SS was 
      possible for 124 (32.8%) of 378 patients. In 51 (41%) of 124, MSGB was essential 
      to reach the number of criteria needed for classification. Of 50 patients 
      evaluated for amyloidosis, 10 (20%) had positive Congo red staining. CONCLUSION: 
      MSGB is a simple, safe, and reliable tool for the diagnosis of SS and 
      amyloidosis, and therefore is suitable for more extensive application.
FAU - Caporali, Roberto
AU  - Caporali R
AD  - Department of Rheumatology, University of Pavia, IRCCS San Matteo Foundation, 
      Pavia, Italy. caporali@smatteo.pv.it
FAU - Bonacci, Eleonora
AU  - Bonacci E
FAU - Epis, Oscar
AU  - Epis O
FAU - Bobbio-Pallavicini, Francesca
AU  - Bobbio-Pallavicini F
FAU - Morbini, Patrizia
AU  - Morbini P
FAU - Montecucco, Carlomaurizio
AU  - Montecucco C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amyloidosis/*pathology
MH  - Biopsy, Needle
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Salivary Gland Diseases/*pathology
MH  - Salivary Glands/*pathology
MH  - Sjogren's Syndrome/*pathology
EDAT- 2008/04/29 09:00
MHDA- 2008/06/18 09:00
CRDT- 2008/04/29 09:00
PHST- 2008/04/29 09:00 [pubmed]
PHST- 2008/06/18 09:00 [medline]
PHST- 2008/04/29 09:00 [entrez]
AID - 10.1002/art.23579 [doi]
PST - ppublish
SO  - Arthritis Rheum. 2008 May 15;59(5):714-20. doi: 10.1002/art.23579.